文献速递外周动脉疾病

西洛他唑对股腘动脉闭塞性疾病腔内治疗远期结局的影响

The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease.
PubMed 文献 · J Vasc Surg · 2024-01-11

这项荟萃分析纳入10项日本临床研究共4721例患者(西洛他唑组1831例 vs 未用西洛他唑组2890例),评估西洛他唑对股腘动脉闭塞性疾病腔内治疗远期结局的影响。西洛他唑与较低的再狭窄风险相关(汇总OR 0.503,95%CI 0.383-0.660,P<.0001),并与较高的12个月和36个月一期通畅率相关,但与靶病变血运重建、大截肢及随访期死亡率无显著关联。

要点

  • 西洛他唑与较低的再狭窄风险相关(汇总OR 0.503,95%CI 0.383-0.660,P<.0001)。
  • 西洛他唑与较高的12个月一期通畅率(OR 3.047,95%CI 1.168-7.946,P=.023)和36个月一期通畅率(OR 1.616,95%CI 1.412-1.850,P<.0001)相关。
  • 西洛他唑与靶病变血运重建、大截肢及随访期死亡率无显著关联。

核心结论

  • 西洛他唑似乎对因动脉粥样硬化性股腘动脉疾病接受腔内治疗患者的1至3年一期通畅率和再狭窄率有正面影响。
  • 本综述未证实西洛他唑对靶病变血运重建和截肢风险有正面影响。

研究设计与样本

  • 系统文献综述与荟萃分析,检索截至2023年9月发表的评估股腘动脉粥样硬化性疾病腔内治疗后远期结局的文献。
  • 纳入标准为比较西洛他唑治疗与未用西洛他唑患者结局的研究,前瞻性和回顾性研究均可。
  • 共纳入10项临床研究,全部在日本进行,包括4721例患者(西洛他唑组1831例 vs 未用西洛他唑组2890例),治疗5703处病变(西洛他唑组2235处 vs 未用西洛他唑组3468处)。
  • 平均随访24.1 ± 12.5个月。

主要发现

  • 西洛他唑与较低的再狭窄风险相关(汇总OR 0.503,95%CI 0.383-0.660,P<.0001)。
  • 西洛他唑与靶病变血运重建无显著关联(汇总OR 0.918,95%CI 0.300-2.812,P=.881)。
  • 西洛他唑与大截肢无显著关联(汇总OR 1.512,95%CI 0.734-3.116,P=.263)。
  • 西洛他唑与较高的12个月一期通畅率相关(OR 3.047,95%CI 1.168-7.946,P=.023),也与较高的36个月一期通畅率相关(OR 1.616,95%CI 1.412-1.850,P<.0001)。
  • 西洛他唑与随访期死亡率无显著关联(汇总OR 0.755,95%CI 0.293-1.946,P=.561)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Restenosis and late occlusion remain a significant problem for endovascular treatment of peripheral artery disease. This meta-analysis aims to evaluate the effect of cilostazol on late outcomes after endovascular repair of occlusive femoropopliteal disease. METHODS: A systematic literature review was conducted conforming to established criteria to identify articles published up to September 2023 evaluating late outcomes after endovascular treatment for atherosclerotic femoropopliteal disease. Eligible studies should compare outcomes between patients treated with cilostazol and patients not treated with cilostazol. Both prospective and retrospective studies were eligible. Late outcomes included primary patency (PP), restenosis, target lesion revascularization (TLR), and major amputation during follow-up. RESULTS: Overall, 10 clinical studies were identified for analysis including 4721 patients (1831 with cilostazol vs 2890 without cilostazol) that were treated for 5703 lesions (2235 with cilostazol vs 3468 without cilostazol). All studies were performed in Japan. Mean follow-up was 24.1 ± 12.5 months. Cilostazol was associated with a lower risk for restenosis (pooled odds ratio [OR], 0.503; 95% confidence interval [CI], 0.383-0.660; P < .0001). However, no association was found between cilostazol and TLR (pooled OR, 0.918; 95% CI, 0.300-2.812; P = .881) as well as major amputation (pooled OR, 1.512; 95% CI, 0.734-3.116; P = .263). Regarding primary patency, cilostazol was associated with a higher 12-month PP (OR, 3.047; 95% CI, 1.168-7.946; P = .023), and a higher 36-month PP (OR, 1.616; 95% CI, 1.412-1.850; P < .0001). No association was found between cilostazol and mortality during follow-up (pooled OR, .755; 95% CI, 0.293-1.946; P = .561). CONCLUSIONS: Cilostazol seems to have a positive effect on 1- to 3-year PP and restenosis rates among patients treated endovascularly for atherosclerotic femoropopliteal disease. A positive effect on TLR and amputation risk was not verified in this review.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Galyfos G, Chamzin A, Saliaris K, et al. The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease. J Vasc Surg. 2024. PMID: 38215952. doi:10.1016/j.jvs.2024.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。